Publications by authors named "Victoria Castel"

Claim this Profile
B
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Lucas Moreno, Rebekah Weston, Cormac Owens, Dominique Valteau-Couanet, Marion Gambart, Victoria Castel, Aurora Castellano

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas.
Eva María Trinidad, Antonio Juan-Ribelles, Giulia Pisano, Victoria Castel, Adela Cañete

Front Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA.
Eva María Trinidad, Enrique Vidal, Esther Coronado, Anna Esteve-Codina, Victoria Castel

Brief Bioinform· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition.
Pablo Gargallo, Silvestre Oltra, María Tasso, Julia Balaguer, Yania Yáñez, Victoria Castel

Eur J Hum Genet· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and Prognostic Impact of Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Angela Bellini, Ulrike Pötschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Victoria Castel

J Clin Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma.
Amparo López-Carrasco, Ana P Berbegall, Susana Martín-Vañó, Maite Blanquer-Maceiras, Victoria Castel

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care.
Pablo Gargallo, Silvestre Oltra, Yania Yáñez, Antonio Juan-Ribelles, Inés Calabria, Victoria Castel

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retinoblastoma and mosaic 13q deletion: a case report.
Pablo Gargallo, Silvestre Oltra, Julia Balaguer, Honorio Barranco, Yania Yáñez, Victoria Castel

Int J Retina Vitreous· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
Gladys G Olivera, Andrea Urtasun, Luis Sendra, Salvador F Aliño, Yania Yáñez, Victoria Castel

Int J Mol Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas.
Antonio Juan Ribelles, Pablo Gargallo, Pablo Berlanga, Vanessa Segura, Yania Yáñez, Victoria Castel

J Pers Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
Esther Coronado, Yania Yañez, Enrique Vidal, Luis Rubio, Francisco Vera-Sempere, Victoria Castel

Mol Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes.
Beatriz Fernández-Blanco, Ana Pilar Berbegall, Susana Martin-Vañó, Victoria Castel, Samuel Navarro

Neoplasia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
Inge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, Nicole Gross, Véronique Mosseri, Victoria Castel

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review: Ewing Sarcoma Predisposition.
Pablo Gargallo, Yania Yáñez, Antonio Juan, Vanessa Segura, Julia Balaguer, Victoria Castel

Pathol Oncol Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
Keith Holmes, Ulrike Pötschger, Andrew D J Pearson, Sabine Sarnacki, Giovanni Cecchetto, Victoria Castel

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Loredana Amoroso, Victoria Castel, Gianni Bisogno, Michela Casanova, Catalina Marquez-Vega

Eur J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and Polymorphisms Improve the Prognostic Value of Status on Overall Survival in Neuroblastoma Patients.
Gladys G Olivera, Yania Yáñez, Pablo Gargallo, Luis Sendra, Salvador F Aliño, Victoria Castel

Int J Mol Sci· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolomic profiling in neuroblastoma.
Guillermo Quintás, Yania Yáñez, Pablo Gargallo, Antonio Juan Ribelles, Adela Cañete, Victoria Castel

Pediatr Blood Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
Antonio Juan Ribelles, Sandra Barberá, Yania Yáñez, Pablo Gargallo, Vanessa Segura, Victoria Castel

Sci Rep· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Maria Rita Castellani

Cancers (Basel)· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
Antonio Juan Ribelles, Sandra Barberá, Yania Yáñez, Pablo Gargallo, Vanessa Segura, Victoria Castel

Sci Rep· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics implementation in the clinics: information and guidelines for germline variants.
Gladys Olivera, Luis Sendra, María José Herrero, Pablo Berlanga, Pablo Gargallo, Victoria Castel

Cancer Drug Resist· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Maria Rita Castellani

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Victoria Castel

Cancers (Basel)· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis